Leqembi Launch Set For Germany & Austria After Winning EU Approval At Last

Concept of a human head with a puzzle in the middle.
Leqembi is the first therapy that targets an underlying cause of AD to be authorized in the EU (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Market Access